

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

18-998/S016

Trade Name: Vasotec Tablets

Generic Name: Enalaprilat

Sponsor: Merck Sharp & Dohme Research Laboratories

Approval Date: January 10, 1989

Indications: The treatment of hypertension.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

18-998/S016

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	
Labeling	X
Medical Review(s)	X
Chemistry Review(s)	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

18-998/S016

APPROVAL LETTER

42.1

JAN 10 1989

NDA 18-998/S-016
19-221/S-002
19-309/S-001

Merck Sharp & Dohme Research Laboratories
Attention: Elliott T. Berger, Ph.D.
Sumneytown Pike
West Point, PA 19486

Dear Dr. Berger:

Please refer to your October 25, 1988 (NDA 18-998) and October 24, 1988 (NDA 19-221 and 19-309) supplemental new drug applications submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Vasotec (enalapril maleate) Tablets (NDA 18-998) and Injection (NDA 19-309), and Vaseretic (enalapril maleate/hydrochlorothiazide) Tablets (NDA 19-221).

The supplemental applications provide for final printed labeling revised to include changes in the following sections:

NDA 18-998, NDA 19-221, and NDA 19-309:

CONTRAINDICATIONS: addition of a drug-class contraindication to use in patients with a history of angioedema related to previous treatment with an ACE inhibitor.

PRECAUTIONS, Drug Interactions, Enalapril Maleate: addition of a statement recommending that caution be used when lithium and enalapril are used concomitantly.

NDA 18-998 AND NDA 19-221:

HOW SUPPLIED: addition of the statement "Dispense in a tight container, if product package is subdivided."

In addition, minor editorial changes have been made in all the package inserts. These package inserts have also been updated for consistency with current approved labeling for enalapril and that for Vaseretic Tablets, for consistency with current approved labeling for hydrochlorothiazide as well.

We have completed the review of these supplemental applications and they are approved. Our letters of December 24, 1985 (NDA 18-998), October 31, 1986 (NDA 19-221), and February 9, 1988 (NDA 19-309) detailed the conditions relating to the approval of these applications.



We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Sincerely yours,

RZ 11/10/89

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:

Original NDA

HFD-110

HFD-110/CSO

HFD-80/DDIR

HFD-100

HFD-232 (with labeling)

HFD-730

HFD-110/KBongiovanni/12/21/88

clb/12/22/88;sb/1/4/89/1307C

R/D: SZimmerman/12/23/88

RWolters/12/23/88

CGraham/12/28/88

NMorgens tern/1/3/89

K. Bongiovanni 1-4-89

man 1/9/89

1-6-89

K. Bongiovanni

APPROVAL

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

18-998/S016

LABELING

NDA 18-998

Labeling: OriginalNDA No: 18-9980Re'd. October 31, 1988

Reviewed by: _____

APPROVED

A.H.F.S. Categories: 24:04, 24:08

7575815

TABLETS


MSD | **VASOTEC®**
(ENALAPRIL MALEATE, MSD)

VASOTEC®
(Enalapril Maleate, MSD)

VASOTEC®
(Enalapril Maleate, MSD)

DESCRIPTION

VASOTEC® (Enalapril Maleate, MSD) is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin converting enzyme inhibitor, enalaprilat. Enalapril maleate is chemically described as (S)-1-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-L-proline, (Z)-2-butenedioate salt (1:1). Its empirical formula is $C_{20}H_{28}N_2O_5 \cdot C_4H_4O_4$, and its structural formula is:



Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. It is sparingly soluble in water, soluble in ethanol, and freely soluble in methanol.

Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat which is the active angiotensin converting enzyme inhibitor.

Enalapril maleate is supplied as 2.5 mg, 5 mg, 10 mg, and 20 mg tablets for oral administration. In addition to the active ingredient enalapril maleate, each tablet contains the following inactive ingredients: lactose, magnesium stearate, starch, and other ingredients. The 2.5 mg, 10 mg and 20 mg tablets also contain iron oxides.

CLINICAL PHARMACOLOGY

Mechanism of Action

Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium. In hypertensive patients treated with VASOTEC alone for up to 48 weeks, mean increases in serum potassium of approximately 0.2 mEq/L were observed. In patients treated with VASOTEC plus a thiazide diuretic, there was essentially no change in serum potassium. (See PRECAUTIONS.) Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.

ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasopressor peptide, play a role in the therapeutic effects of VASOTEC remains to be elucidated.

While the mechanism through which VASOTEC lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, VASOTEC is antihypertensive even in patients with low-renin hypertension. Although VASOTEC was antihypertensive in all races studied, black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to enalapril monotherapy than non-black patients.

Pharmacokinetics and Metabolism

Following oral administration of VASOTEC, peak serum concentrations of enalapril occur within about one hour. Based on urinary recovery, the extent of absorption of enalapril is approximately 60 percent. Enalapril absorption is not influenced by the presence of food in the gastrointestinal tract. Following absorption, enalapril is hydrolyzed to enalaprilat, which is a more potent angiotensin converting enzyme inhibitor than enalapril; enalaprilat is poorly absorbed when administered orally. Peak serum concentrations of enalaprilat occur three to four hours after an oral dose of enalapril maleate. Excretion of VASOTEC is primarily renal. Approximately 94 percent of the dose is recovered in the urine and feces as enalaprilat or enalapril. The principal components in urine are enalaprilat, accounting for about 40 percent of the dose, and intact enalapril. There is no evidence of metabolites of enalapril, other than enalaprilat.

The serum concentration profile of enalaprilat exhibits a prolonged terminal phase, apparently representing a small fraction of the administered dose that has been bound to ACE. The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-life for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours.

The disposition of enalapril and enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. With renal function ≤ 30 mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases and time to steady state may be delayed. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency. (See DOSAGE AND ADMINISTRATION.) Enalaprilat is dialyzable at the rate of 62 mL/min.

*Registered trademark of MERCK & CO., Inc.
COPYRIGHT © MERCK & CO., Inc., 1987, 1988
All rights reserved

Studies in dogs indicate that enalapril crosses the blood-brain barrier poorly, if at all; enalaprilat does not enter the brain. Multiple doses of enalapril maleate in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration of ^{14}C enalapril maleate. Radioactivity was found to cross the placenta following administration of labeled drug to pregnant hamsters.

Pharmacodynamics and Clinical Effects

Hypertension: Administration of VASOTEC to patients with hypertension of severity ranging from mild to severe results in a reduction of both supine and standing blood pressure usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients. (See WARNINGS.)

In most patients studied, after oral administration of a single dose of enalapril, onset of antihypertensive activity was seen at one hour with peak reduction of blood pressure achieved by four to six hours.

At recommended doses, antihypertensive effects have been maintained for at least 24 hours. In some patients the effects may diminish toward the end of the dosing interval (see DOSAGE AND ADMINISTRATION).

In some patients achievement of optimal blood pressure reduction may require several weeks of therapy.

The antihypertensive effects of VASOTEC have continued during long term therapy. Abrupt withdrawal of VASOTEC has not been associated with a rapid increase in blood pressure.

In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate. Following administration of VASOTEC, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.

When given together with thiazide-type diuretics, the blood pressure lowering effects of VASOTEC are approximately additive.

In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC.

Heart Failure: In trials in patients treated with digitalis and diuretics, treatment with enalapril resulted in decreased systemic vascular resistance, blood pressure, pulmonary capillary wedge pressure, and heart size, and increased cardiac output and exercise tolerance. Heart rate was unchanged or slightly reduced, and mean ejection fraction was unchanged or increased. There was a beneficial effect on severity of heart failure as measured by the New York Heart Association (NYHA) classification and on symptoms of dyspnea and fatigue. Hemodynamic effects were observed after the first dose, and appeared to be maintained in uncontrolled studies lasting as long as four months. Effects on exercise tolerance, heart size, and severity and symptoms of heart failure were observed in placebo-controlled studies lasting from eight weeks to over one year.

A Scandinavian multicenter trial compared the effects of enalapril and placebo on mortality in 263 patients with severe heart failure (NYHA Class IV) and radiographic evidence of cardiomegaly who were maintained on therapy with diuretics and digitalis. Other vasodilators were used as needed. In the enalapril group, the reduction in all-cause mortality was 40 percent after six months and 31 percent after one year. There was an improvement in NYHA classification, a reduction in heart size, and a lessened need for concomitant vasodilator therapy in the enalapril group.

INDICATIONS AND USAGE

Hypertension

VASOTEC is indicated for the treatment of hypertension. VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive.

Heart Failure

VASOTEC is indicated as adjunctive therapy in the management of heart failure, in patients who are not responding adequately to diuretics and digitalis.

In a multicenter placebo-controlled trial in patients with severe heart failure (New York Heart Association Class IV) and radiographic evidence of cardiomegaly who were maintained on therapy with diuretics and digitalis, patients who received VASOTEC had a 40 percent reduction in mortality after six months and a 31 percent reduction after one year. (See CLINICAL PHARMACOLOGY.)

VASOTEC is to be used with diuretics and digitalis.

In using VASOTEC consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that VASOTEC does not have a similar risk. (See WARNINGS.)

CONTRAINDICATIONS

VASOTEC is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor.

7575815

VASOTEC®
(Enalapril Maleate, MSD)

WARNINGS

Angioedema

Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including VASOTEC. In such cases VASOTEC should be promptly discontinued and the patient carefully observed until the swelling disappears. In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) should be promptly administered. (See ADVERSE REACTIONS.)

Hypotension

Excessive hypotension is rare in uncomplicated hypertensive patients treated with VASOTEC alone. Heart failure patients given VASOTEC commonly have some reduction in blood pressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy. (See DOSAGE AND ADMINISTRATION.) Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hypotension, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic (except in heart failure patients), reduce the diuretic dose or increase salt intake cautiously before initiating therapy with VASOTEC in patients at risk for excessive hypotension who are able to tolerate such adjustments. (See PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS.) In patients at risk for excessive hypotension, therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If excessive hypotension occurs, the patient should be placed in supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of VASOTEC which usually can be given without difficulty once the blood pressure has stabilized. If symptomatic hypotension develops, a dose reduction or discontinuation of VASOTEC or concomitant diuretic may be necessary.

Neutropenia/Agranulocytosis

Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause agranulocytosis at similar rates. Foreign marketing experience has revealed several cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

PRECAUTIONS

General

Impaired Renal Function: As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including VASOTEC, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death.

In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.

Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when VASOTEC has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or VASOTEC may be required.

Evaluation of patients with hypertension or heart failure should always include assessment of renal function. (See DOSAGE AND ADMINISTRATION.)

Hyperkalemia: Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately one percent of hypertensive patients in clinical trials. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in 0.28 percent of hypertensive patients. In clinical trials in heart failure, hyperkalemia was observed in 3.8 percent of patients but was not a cause for discontinuation.

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with VASOTEC. (See Drug Interactions.)

Surgery/Anesthesia: In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Information for Patients

Angioedema: Angioedema, including laryngeal edema, may occur especially following the first dose of enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, ex-

VASOTEC®
(Enalapril Maleate, MSD)

trémities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

Hypotension: Patients should be cautioned to report lightheadedness especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician. All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.

Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions

Hypotension—Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION.)

Agents Causing Renin Release: The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).

Other Cardiovascular Agents: VASOTEC has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.

Agents Increasing Serum Potassium: VASOTEC attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Potassium sparing agents should generally not be used in patients with heart failure receiving VASOTEC.

Lithium: A few cases of lithium toxicity have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs. Although a causal relationship has not been established, it is recommended that caution be exercised when lithium is used concomitantly with VASOTEC and serum lithium levels should be monitored frequently.

Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no evidence of a tumorigenic effect when enalapril was administered for 106 weeks to rats at a dose up to 90 mg/kg/day (150 times the maximum daily human dose). Enalapril has also been administered for 94 weeks to male and female mice at doses up to 90 and 180 mg/kg/day, respectively, (150 and 300 times the maximum daily dose for humans) and showed no evidence of carcinogenicity.

Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril was also negative in the following genotoxicity studies: rec-assay, reverse mutation assay with *E. coli*, sister chromatid exchange with cultured mammalian cells, and the micronucleus test with mice, as well as in an *in vivo* cytogenetic study using mouse bone marrow.

There were no adverse effects on reproductive performance in male and female rats treated with 10 to 90 mg/kg/day of enalapril.

Pregnancy

Pregnancy Category C. There was no fetotoxicity or teratogenicity in rats treated with up to 200 mg/kg/day of enalapril (333 times the maximum human dose). Fetotoxicity, expressed as a decrease in average fetal weight, occurred in rats given 1200 mg/kg/day of enalapril, but did not occur when these animals were supplemented with saline. Enalapril was not teratogenic in rabbits. However, maternal and fetal toxicity occurred in some rabbits at doses of 1 mg/kg/day or more. Saline supplementation prevented the maternal and fetal toxicity seen at doses of 3 and 10 mg/kg/day, but not at 30 mg/kg/day (50 times the maximum human dose).

Radioactivity was found to cross the placenta following administration of labeled enalapril to pregnant hamsters.

There are no adequate and well-controlled studies in pregnant women. VASOTEC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Milk in lactating rats contains radioactivity following administration of ¹⁴C enalapril maleate. It is not known whether this drug is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when VASOTEC is given to a nursing mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

VASOTEC has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more. VASOTEC has been found to be generally well tolerated in controlled clinical trials involving 2987 patients.

For the most part, adverse experiences were mild and transient in nature. In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in

VASOTEC®
(Enalapril Maleate, MSD)

3.3 percent of patients with hypertension and in 5.7 percent of patients with heart failure. The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges. In patients with hypertension the overall percentage of patients treated with VASOTEC reporting adverse experiences was comparable to placebo.

Hypertension

Adverse experiences occurring in greater than one percent of patients with hypertension treated with VASOTEC in controlled clinical trials are shown below. In patients treated with VASOTEC, the maximum duration of therapy was three years; in placebo treated patients the maximum duration of therapy was 12 weeks.

	VASOTEC (n=2314) Incidence (discontinuation)	Placebo (n=230) Incidence
Body As A Whole		
Fatigue	3.0 (<0.1)	2.6
Orthostatic Effects	1.2 (<0.1)	0.0
Asthenia	1.1 (0.1)	0.9
Digestive		
Diarrhea	1.4 (<0.1)	1.7
Nausea	1.4 (0.2)	1.7
Nervous/Psychiatric		
Headache	5.2 (0.3)	9.1
Dizziness	4.3 (0.4)	4.3
Respiratory		
Cough	1.3 (0.1)	0.9
Skin		
Rash	1.4 (0.4)	0.4

Heart Failure

Adverse experiences occurring in greater than one percent of patients with heart failure treated with VASOTEC are shown below. The incidences represent the experiences from both controlled and uncontrolled clinical trials (maximum duration of therapy was approximately one year). In the placebo treated patients, the incidences reported are from the controlled trials (maximum duration of therapy is 12 weeks). The percentage of patients with severe heart failure (NYHA Class IV) was 29 percent and 43 percent for patients treated with VASOTEC and placebo, respectively.

	VASOTEC (n=673) Incidence (discontinuation)	Placebo (n=339) Incidence
Body As A Whole		
Orthostatic Effects	2.2 (0.1)	0.3
Syncopal	2.2 (0.1)	0.9
Chest Pain	2.1 (0.0)	2.1
Fatigue	1.8 (0.0)	1.8
Abdominal Pain	1.6 (0.4)	2.1
Asthenia	1.6 (0.1)	0.3
Cardiovascular		
Hypotension	6.7 (1.9)	0.6
Orthostatic Hypotension	1.6 (0.1)	0.3
Angina Pectoris	1.5 (0.1)	1.8
Myocardial Infarction	1.2 (0.3)	1.8
Digestive		
Diarrhea	2.1 (0.1)	1.2
Nausea	1.3 (0.1)	0.6
Vomiting	1.3 (0.0)	0.9
Nervous/Psychiatric		
Dizziness	7.9 (0.6)	0.6
Headache	1.8 (0.1)	0.9
Vertigo	1.6 (0.1)	1.2
Respiratory		
Cough	2.2 (0.0)	0.6
Bronchitis	1.3 (0.0)	0.9
Dyspnea	1.3 (0.1)	0.4
Pneumonia	1.0 (0.0)	2.4
Skin		
Rash	1.3 (0.0)	2.4
Urogenital		
Urinary Tract Infection	1.3 (0.0)	2.4

Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in 0.5 to 1.0 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity.

Cardiovascular: Myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see WARNINGS, Hypotension); cardiac arrest; pulmonary embolism and infarction; rhythm disturbances; atrial fibrillation; palpitation.

Digestive: Ileus, pancreatitis, hepatitis or cholestatic jaundice, melena, anorexia, dyspepsia, constipation, glossitis.

Nervous/Psychiatric: Depression, confusion, ataxia, somnolence, insomnia, nervousness, paresthesia.

Respiratory: Bronchospasm, rhinorrhea, asthma, upper respiratory infection.

Skin: Herpes zoster, pruritus, alopecia, flushing, photosensitivity.

Urogenital: Renal failure, oliguria, renal dysfunction (see PRECAUTIONS AND DOSAGE AND ADMINISTRATION), impotence, prostate hypertrophy.

Other: Muscle cramps, hyperhidrosis, blurred vision, taste alteration, tinnitus.

VASOTEC®
(Enalapril Maleate, MSD)

A symptom complex has been reported which may include fever, myalgia and arthralgia; an elevated erythrocyte sedimentation rate may be present. Rash or other dermatologic manifestations may occur. These symptoms have disappeared after discontinuation of therapy.

Angioedema: Angioedema has been reported in patients receiving VASOTEC (0.2 percent). Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with VASOTEC should be discontinued and appropriate therapy instituted immediately. (See WARNINGS.)

Hypotension: In the hypertensive patients, hypotension occurred in 0.9 percent and syncope occurred in 0.5 percent of patients following the initial dose or during extended therapy. Hypotension or syncope was a cause for discontinuation of therapy in 0.1 percent of hypertensive patients. In heart failure patients, hypotension occurred in 6.7 percent and syncope occurred in 2.2 percent of patients. Hypotension or syncope was a cause for discontinuation of therapy in 1.9 percent of patients with heart failure. (See WARNINGS.)

Clinical Laboratory Test Findings

Serum Electrolytes: Hyperkalemia (see PRECAUTIONS), hyponatremia.

Creatinine, Blood Urea Nitrogen: In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.2 percent of patients with essential hypertension treated with VASOTEC alone. Increases are more likely to occur in patients receiving concomitant diuretics or in patients with renal artery stenosis. (See PRECAUTIONS.) In patients with heart failure who were also receiving diuretics with or without digitalis increases in blood urea nitrogen or serum creatinine, usually reversible upon discontinuation of VASOTEC and/or other concomitant diuretic therapy, were observed in about 11 percent of patients. Increases in blood urea nitrogen or creatinine were a cause for discontinuation in 1.2 percent of patients.

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.3 g percent and 1.0 vol percent, respectively) occur frequently in either hypertension or congestive heart failure patients treated with VASOTEC but are rarely of clinical importance unless another cause of anemia coexists. In clinical trials, less than 0.1 percent of patients discontinued therapy due to anemia.

Other (Causal Relationship Unknown): In marketing experience, rare cases of neutropenia, thrombocytopenia, and bone marrow depression have been reported.

Liver Function Tests: Elevations of liver enzymes and/or serum bilirubin have occurred.

OVERDOSAGE

Limited data are available in regard to overdosage in humans. The oral LD₅₀ of enalapril is 2000 mg/kg in mice and rats. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution. Enalaprilat may be removed from general circulation by hemodialysis.

DOSAGE AND ADMINISTRATION

Hypertension

In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of VASOTEC. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with VASOTEC to reduce the likelihood of hypotension. (See WARNINGS.) If the patient's blood pressure is not controlled with VASOTEC alone, diuretic therapy may be resumed.

If the diuretic cannot be discontinued an initial dose of 2.5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, Drug Interactions.)

The recommended initial dose in patients not on diuretics is 5 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 10 to 40 mg per day administered in a single dose or two divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients, an increase in dosage or twice daily administration should be considered. If blood pressure is not controlled with VASOTEC alone, a diuretic may be added.

Concomitant administration of VASOTEC with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see PRECAUTIONS).

Dosage Adjustment in Hypertensive Patients with Renal Impairment

The usual dose of enalapril is recommended for patients with a creatinine clearance >30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance ≤30 mL/min (serum creatinine ≥3 mg/dL), the first dose is 2.5 mg once daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.

7575815

VASOTEC®
(Enalapril Maleate, MSD)

Renal Status	Creatinine-Clearance mL/min	Initial Dose mg/day
Normal Renal Function	>80 mL/min	5 mg
Mild Impairment	≤80 >30 mL/min	5 mg
Moderate to Severe Impairment	≤30 mL/min	2.5 mg
Dialysis Patients	—	2.5 mg on dialysis days*

*Dosage on nondialysis days should be adjusted depending on the blood pressure response.

Heart Failure
VASOTEC is indicated as adjunctive therapy with diuretics and digitalis. The recommended starting dose is 2.5 mg once or twice daily. After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, *Drug Interactions*.) If possible, the dose of the diuretic should be reduced which may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. The usual therapeutic dosing range for the treatment of heart failure is 5 to 20 mg daily given in two divided doses. The maximum daily dose is 40 mg. Once daily dosing has been effective in a controlled study, but nearly all patients in this study were given 40 mg with twice daily dosing. In addition, patients in the mortality trial received therapy with twice daily dosing. (See WARNINGS.)

In a placebo-controlled study which demonstrated reduced mortality in patients with severe heart failure (NYHA Class IV), patients were treated with 2.5 - 40 mg per day of VASOTEC, almost always administered in two divided doses. (See CLINICAL PHARMACOLOGY, *Pharmacodynamics and Clinical Effects*.)

VASOTEC®
(Enalapril Maleate, MSD)

Dosage Adjustment in Heart Failure Patients with Renal Impairment or Hyponatremia
In heart failure patients with hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision. (See DOSAGE AND ADMINISTRATION, *Heart Failure*, WARNINGS and PRECAUTIONS, *Drug Interactions*.) The dose may be increased to 2.5 mg b.i.d., then 5 mg b.i.d. and higher as needed, usually at intervals of four days or more if at the time of dosage adjustment there is not excessive hypotension or significant deterioration of renal function. The maximum daily dose is 40 mg.

HOW SUPPLIED

No. 3411 — Tablets VASOTEC, 2.5 mg, are yellow, biconvex barrel shaped, scored, compressed tablets with code MSD 014 on one side and VASOTEC on the other. They are supplied as follows:

NDC 0006-0014-68 bottles of 100 (with desiccant)

(6505-01-236-8880, 5 mg 100's)

No. 3412 — Tablets VASOTEC, 5 mg, are white, barrel shaped, scored, compressed tablets, with code MSD 712 on one side and VASOTEC on the other. They are supplied as follows:

NDC 0006-0712-68 bottles of 100 (with desiccant)

(6505-01-236-8880, 5 mg 100's)

No. 3413 — Tablets VASOTEC, 10 mg, are salmon, barrel shaped, compressed tablets, with code MSD 713 on one side and VASOTEC on the other. They are supplied as follows:

NDC 0006-0713-68 bottles of 100 (with desiccant)

(6505-01-236-8881, 10 mg 100's)

No. 3414 — Tablets VASOTEC, 20 mg, are peach, barrel shaped, compressed tablets, with code MSD 714 on one side and VASOTEC on the other. They are supplied as follows:

NDC 0006-0714-68 bottles of 100 (with desiccant)

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

NDC 0006-0714-28 unit dose packages of 100.

(6505-01-237-0545, 20 mg 100's)

MSD MERCK SHARP & DOHME
DIV OF MERCK & CO., INC., WEST POINT, PA 19386, USA

Printed in USA

Issued October 1988

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

18-998/S016

MEDICAL REVIEW

351
Division of Cardio-Renal Drug Products
Medical Officer's Review

NOV 28

Number: NDA 18-998/S016
Drug Name: VASOTEC (enalapril maleate)
Sponsor: Merck

Submission Type: Supplemental Application #016
Submission Date: 25 October 1988
Date of Receipt: 7 November 1988
Review Complete: 28 November 1988

Content:

This is a SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED. It is part of a package of supplements prepared by the sponsor to update the labeling for VASOTEC, VASOTEC I.V. and VASERETIC. Therefore the specific changes in the label for each product are nearly identical except for some minor editorial changes.

Assessment:

The review of the VASOTEC I.V. supplement (NDA 19-309) containing similar changes is attached in lieu of a separate review for this product. The only additional change to the VASOTEC package insert not mentioned in the VASOTEC I.V. supplement is several additional statements in the PREGNANCY and NURSING MOTHERS subsections of the PRECAUTIONS section. The statements were already included in the CLINICAL PHARMACOLOGY section of the labeling and therefore do not contain new information.

Plan:

The changes proposed by the sponsor are supported by the information submitted and should be permitted.


Cheryl Fossum Graham, M.D.

cc:
Orig. NDA 18-998
HFD-110
HFD-110/CSO
HFD-110/CGraham

MM# 18998S16/cfg/28nov88